|
Orthologous residues
|
|
PML (human): S565‑p, PML iso2 (human): S565‑p, PML iso3 (human): S565‑p, PML iso4 (human): ‑, PML iso11 (human): S517‑p, PML iso14 (human): ‑, PML (mouse): S575‑p, PML iso2 (mouse): S529‑p, PML (rat): S563‑p
|
|
Characterization
|
|
Methods used to characterize site in vivo:
mutation of modification site, phospho-antibody, western blotting
|
|
Disease tissue studied:
colorectal cancer, colorectal carcinoma
|
|
Relevant cell lines - cell types - tissues:
293 (epithelial), 3T3 (fibroblast), Colo-320 (intestinal), MEF (fibroblast), WI-38 (fibroblast)
|
|
Cellular systems studied:
cell lines
|
|
Species studied:
human, mouse
|
|
Enzymes shown to modify site in vitro:
|
|
|
|
Upstream Regulation
|
|
Potential in vivo enzymes for site:
|
|
Type
|
Enzyme
|
Evidence
|
Notes
|
|
KINASE
|
CK2-A1 (human)
|
modification site within consensus motif, phospho-antibody, siRNA inhibition of enzyme, pharmacological activator of upstream enzyme, microscopy-colocalization, pharmacological inhibitor of upstream enzyme
|
|
|
|
Treatments, proteins and their effect on site modification:
|
|
Treatments
|
Referenced Treatments
|
Manipulated Protein
|
Referenced Protein
|
Effect
|
Notes
|
|
osmotic stress
|
|
|
|
increase
|
|
|
UV
|
|
|
|
increase
|
|
|
TBB
|
UV
|
|
|
inhibit treatment-induced increase
|
|
|
|
Downstream Regulation
|
|
Effect of modification (function):
protein degradation
|
|
Effect of modification (process):
apoptosis, inhibited, cell growth, altered
|
